Background:

CMK is a RSK2 kinase inhibitor which exhibits similar potency but less chemical stability compared with FMK.

CMK inhibits the growth of Cdc5 (L158G) with IC50 of 36 nM, greater than 30 μM for wild type Cdc5. CMK exhibits a concentration-dependent first cell cycle mitotic arrest in the cdc5-as1 strain with an IC50 of 1.1 μM. CMK inhibition of Cdc5 (L158G) leads to a first cell cycle anaphase arrest and delay in anaphase spindle migration[1].

参考文献:
[1]. Snead JL, et al. A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol. 2007 Nov;14(11):1261-72.